



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 29/00 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/079976

(22) International Filing Date:

16 November 2022 (16.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/280,463 17 November 2021 (17.11.2021) US

(71) Applicant: ALTRUBIO INC. [US/US]; 1209 Orange Street, Wilmington, Delaware 19801 (US).

(72) Inventors: LIN, Shih-Yao; 7F., No. 1, Lane 105, Lishan Street, Neihu District, Taipei, 114 (TW). CHIANG, Feng-Lin; No. 97, Fuxing 4th Road, Beitou District, Taipei City,


112 (TW). YEH, You-Chia; Rm. 2, 3F., No. 4, Ln. 12, Wan'an St., Wenshan District, Taipei (TW).

(74) Agent: JONES, Kevin et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: METHODS OF USING ANTI-PSGL-1 ANTIBODIES IN COMBINATION WITH JAK INHIBITORS TO TREAT T-CELL MEDIATED INFLAMMATORY DISEASES OR CANCERS



Donor 1

FIG. 1A

(57) Abstract: Provided herein are methods of treating or preventing a T-cell mediated inflammatory disease or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds to human PSGL-1 in combination with a Janus kinase (JAK) inhibitor. In some embodiments, the T-cell mediated inflammatory disease is GVHD, e.g., acute GVHD or chronic GVHD.

[Continued on next page]

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*